Ignite Creation Date:
2025-12-24 @ 9:30 PM
Ignite Modification Date:
2026-01-20 @ 6:53 AM
Study NCT ID:
NCT04982432
Status:
UNKNOWN
Last Update Posted:
2021-09-28
First Post:
2021-07-26
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Orismilast for the Treatment of Mild to Severe Hidradenitis Suppurativa
Sponsor:
Gregor Jemec
Organization:
Study Overview
Official Title:
Orismilast for the Treatment of Mild to Severe Hidradenitis Suppurativa (OSIRIS)
Status:
UNKNOWN
Status Verified Date:
2021-09
Last Known Status:
NOT_YET_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
OSIRIS
Brief Summary:
The purpose of this study is to assess the efficacy and safety of oral administration of orismilast for treatment of mild, moderate, or severe hidradenitis suppurativa (HS) in adults.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| 2021-000049-42 | EUDRACT_NUMBER | None | View |